Patients with type 1 or type 2 diabetes mellitus are at increased risk of cardiovascular disease (CVD). In this Review, the author discusses available data from randomized controlled trials of statins and other dyslipidemia-management agents that provide a framework to guide primary and secondary prevention of CVD in these populations.